TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Perspective Therapeutics
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium

Perspective Therapeutics will present updated data on its [212Pb]VMT-α-NET program at the ASCO Gastrointestinal Cancers Symposium in January 2026, highlighting promising safety and efficacy results for neuroendocrine tumor treatment.

Insights
TSM   neutral

Mentioned as a semiconductor company, part of the PHLX Semiconductor Sector index that rose 217% in three years


CATX   positive

Company reported favorable safety profile in clinical trials, with 80% of patients remaining progression-free and 44% achieving confirmed responses in a subset of patients with SSTR2 expression